Royal United Hospitals Bath NHS Foundation Trust

Bath BA1 3NH

4 studies enrolling now · 8 studies all time

What they study most

Advanced Breast Cancer, Atopic Dermatitis, Breast Cancer, Cardiovascular Diseases, Cardiovascular Risk Factors, Follicular Lymphoma, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer, Metastatic Breast Cancer, PIK3CA Mutation, Pulmonary Arterial Hypertension (PAH)

Studies at this site

• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer — Recruiting now
• Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH) — Recruiting now
• The Oxford Risk Factors And Non-Invasive Imaging Study — Recruiting now
• A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD — Recruiting now
• A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD) — Completed
• Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS) — Running, not enrolling
• A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) — Completed
• A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) — Completed